S1P-targeted therapy for elderly rheumatoid arthritis patients with osteoporosis
S1P-targeted therapy for elderly rheumatoid arthritis patients with osteoporosis
复制标题
DOI：
10.1007/s00296-010-1634-8
复制
发表时间：
2011-07-01
影响因子：
4
通讯作者：
Ishii, Masaru
中科院分区：
文献类型：
--
作者：
Kikuta, Junichi;Iwai, Kaori;Ishii, Masaru
鞘氨醇-1-磷酸（S1 P）是一种调节免疫细胞转运的脂质介质，近年来作为治疗类风湿性关节炎（RA）等自身免疫性疾病的一种新的治疗方案而迅速兴起。在这里，我们提出，S1 P靶向治疗不仅有利于限制炎症，但对于预防骨吸收疾病，如骨质疏松症，通过控制破骨细胞前体的迁移行为，因此将是好的治疗老年女性RA患者患有绝经后骨质疏松症和关节炎的同时。
Therapeutics targeting sphingosine-1-phosphate (S1P), a kind of lipid mediator regulating immune cell trafficking, has been emerging rapidly as a novel line of regimen for autoimmune diseases, including rheumatoid arthritis (RA). Here, we propose that S1P-targeted therapy is beneficial not only for limiting inflammation but for preventing bone-resorptive disorders, such as osteoporosis, by controlling the migratory behavior of osteoclast precursors and therefore would be good for treating elderly female RA patients who suffer from postmenopausal osteoporosis and arthritis simultaneously.